Thyroid disorders in autoimmune polyendocrinopathy

Salah Dhoha Ben; Oumaima Dimassi; Khouloud Boujelben; Abdallah Ameni Ben; Kacem Akid Faten Haj; Nadia Charfi; Mouna Mnif; Mohamed Abid; Mouna Elleuch; Majdoub Nabila Rekik

doi:10.1530/endoabs.110.EP1514

EP1514

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP1514 | DOI: 10.1530/endoabs.110.EP1514

ECEESPE2025 ePoster Presentations Thyroid (198 abstracts)

Thyroid disorders in autoimmune polyendocrinopathy

Dhoha Ben Salah ¹ , Oumaima Dimassi ¹ , Khouloud Boujelben ¹ , Ameni Ben Abdallah ¹ , Faten Haj Kacem Akid ¹ , Nadia Charfi ¹ , Mouna Mnif ¹ , Mohamed Abid ¹ , Mouna Elleuch ¹ & Nabila Rekik Majdoub ¹

Author affiliations

¹Department of Endocrinology Hedi Chaker Hospital, Sfax, Tunisia

JOINT2507

Objective: To evaluate the characteristics of autoimmune thyroid diseases (AITD) occurring within the context of autoimmune polyendocrinopathy (APE).

Patients and Methods: This was a retrospective study including 41 patients diagnosed with APE involving AITD, hospitalized in the Endocrinology Department of Hedi Chaker University Hospital, Sfax, between 2009 and 2019.

Results: The mean age at diagnosis was 32.6 ± 15.3 years, with a female predominance. Hashimoto’s thyroiditis was identified in 33 cases, while Graves’ disease was present in 8 cases. The most common association was with type 1 diabetes (68.3%), followed by Addison’s disease (36.6%). Other associated autoimmune conditions included primary ovarian insufficiency, autoimmune hypophysitis, celiac disease, chronic mucocutaneous candidiasis, myasthenia gravis, vitiligo, and hypoparathyroidism, each occurring in one case. AITD was classified within APE type 3 in 22 cases, APE type 2 in 16 cases, and APE type1 in one case. Additionally, chromosomal anomalies, specifically trisomy 21, were observed in two cases. The first clinical manifestation was type 1 diabetes in 48.8% of cases, AITD in 29.3%, and Addison’s disease in 14.6%.

Conclusion: AITD is an organ-specific autoimmune disorder that can coexist with systemic autoimmune diseases, suggesting a shared immune mechanism. This expands the spectrum of multiple autoimmune syndromes, necessitating vigilant clinical and biological monitoring, particularly for thyroid function.